ArticleHepatology international2026

Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation.

Jesus Gibran Hernández-Pérez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.